ArticleFertility and sterility2021
Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels.
Article in Fertility and sterility, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Anti-Müllerian hormone decreased in women with superficial peritoneal endometriosis and associated with an elevated inflammatory profile.Reproduction & fertility · 2026Article
- Endometriosis and Fertility: A Practical Guide: Results of the Working Group of the Weissensee 2025 Workshop of the Scientific Endometriosis Foundation.Geburtshilfe und Frauenheilkunde · 2026Article
- The effects of intrauterine devices on anti-Mullerian hormone levels-a mini-review.Gynecology and pelvic medicine · 2026Review
- Hyperresponse during ovarian stimulation despite profoundly suppressed ovarian reserve markers in a patient with long-term combined hormonal contraceptive use.F&S reports · 2025Article
- Endometriosis and infertility: pathophysiology, treatment strategies, and reproductive outcomes.Archives of gynecology and obstetrics · 2025Review
- Age-related Curves of AMH Using the Gen II, the picoAMH, and the Elecsys Assays in Women With Polycystic Ovary Syndrome.The Journal of clinical endocrinology and metabolism · 2024Article
- The impact of sickle cell disease and its treatment on ovarian reserve in reproductive-aged Black women.British journal of haematology · 2024Article
- Association between serum 25-hydroxyvitamin D and antimüllerian hormone levels in a cohort of African-American women.Fertility and sterility · 2024Article
- Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions.Human reproduction (Oxford, England) · 2024Article
- Emerging biomarkers for improving pregnancy planning in multiple sclerosis.Frontiers in neurology · 2024Article
- Article
- The Stability of the Anti-Müllerian Hormone in Serum and Plasma Samples under Various Preanalytical Conditions.Diagnostics (Basel, Switzerland) · 2023Article
- Hormonal contraception and risk for cognitive impairment or Alzheimer's disease and related dementias in young women: a scoping review of the evidence.Frontiers in global women's health · 2023Article
- Potential biomarkers to predict return to fertility after discontinuation of female contraceptives-looking to the future.Frontiers in reproductive health · 2023Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
objectiveTo assess whether the duration, recency, or type of hormonal contraceptive used is associated with antimüllerian hormone (AMH) levels, given that the existing literature regarding the association between hormonal contraceptive use and AMH levels is inconsistent.
designCross-sectional study.
settingBaseline data from the Study of the Environment, Lifestyle and Fibroids Study, a 5-year longitudinal study of African American women. PATIENT(S): The patients were 1,643 African American women aged 23-35 years at the time of blood drawing (2010-2012). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Serum AMH level was measured by an ultrasensitive enzyme-linked immunosorbent assay. Linear regression models were used to estimate percent differences in mean AMH levels and 95% confidence intervals (CIs) according to use of hormonal contraceptives, with adjustment for potential confounders. RESULT(S): In multivariable-adjusted analyses, current users of hormonal contraceptives had 25.2% lower mean AMH levels than non-users of hormonal contraceptives (95% CI: -35.3%, -13.6%). There was little difference in AMH levels between former users and non-users of hormonal contraceptives (-4.4%; 95% CI: -16.3%, 9.0%). AMH levels were not appreciably associated with cumulative duration of use among former users or time since last use among non-current users. Current users of combined oral contraceptives (-24.0%; 95% CI: -36.6%, -8.9%), vaginal ring (-64.8%; 95% CI: -75.4%, -49.6%), and depot medroxyprogesterone acetate (-26.7%; 95% CI: -41.0%, -8.9%) had lower mean AMH levels than non-users. CONCLUSION(S): The present data suggest that AMH levels are significantly lower among current users of most forms of hormonal contraceptives, but that the suppressive effect of hormonal contraceptives on AMH levels is reversible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.